Trading a UNCY straddle lets you take a pure volatility position on Unicycive Therapeutics Inc without committing to a direction. Unicycive Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate UNCY straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on UNCY profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Unicycive Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the UNCY straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the UNCY straddle is the cleanest expression of that view. Our scanner prices every UNCY straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a UNCY straddle into a catalyst or short a UNCY straddle to harvest decay, the options straddle setups that matter are all in one place.
